Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
This trial is designed as a phase 2 randomized, double-blind double dummy, active comparator
controlled, two-period two-arm crossover study to enroll 40 patients across multiple centers.
The study will compare platelet function following a prasugrel loading dose and 1 week of
prasugrel maintenance therapy with high-dose clopidogrel loading dose and 1 week of high-dose
clopidogrel maintenance therapy in patients with drug treated type 2 diabetes mellitus who
have coronary artery disease. Various assays of platelet function will be used in this study.
Platelet function will be studied using the following assays: Accumetrics VerifyNowTM P2Y12,
Light Transmittance Aggregometry (LTA), Vasodilator-associated stimulated phosphoprotein
(VASP), and Thromboelastography (TEG)-platelet mapping.